Madsbad, Sten

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines

Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 43

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Iepsen, E. W., Have, C. T., Veedfald, S., Madsbad, S., Holst, J. J., Grarup, N., Pedersen, O., Brandslund, I., Holm, J.-C., Hansen, T., et al. (2020) · Cell Reports Medicine

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 43

Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment

Jensen, S. B. K., Janus, C., Lundgren, J. R., Juhl, C. R., Sandsdal, R. M., Olsen, L. M., Andresen, A., Borg, S. A., Jacobsen, I. C., Finlayson, G., et al. (2022) · Nature Communications

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 42

Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes

Ranjan, A., Schmidt, S., Madsbad, S., Holst, J. J., & Nørgaard, K. (2016) · Diabetes, Obesity and Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 39

Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

Østergaard, L., Frandsen, C. S., & Madsbad, S. (2016) · Expert Review of Clinical Pharmacology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 38

Skeletal muscle mitochondrial function in polycystic ovarian syndrome

Rabøl, R., Svendsen, P. F., Skovbro, M., Boushel, R., Schjerling, P., Nilas, L., Madsbad, S., & Dela, F. (2011) · European Journal of Endocrinology

Ovarian function and disordersMitochondrial Function and Pathology

Cited by 33

Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes

Schmidt, S., Frandsen, C. S., Dejgaard, T. F., Vistisen, D., Halldórsson, T., Olsen, S. F., Jensen, J. B., Madsbad, S., Andersen, H. U., & Nørgaard, K. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 29

Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double‐blind, placebo‐controlled trial

Dejgaard, T. F., Frandsen, C. S., Kielgast, U., Størling, J., Overgaard, A. J., Svane, M. S., Olsen, M. H., Thorsteinsson, B., Andersen, H. U., Krarup, T., et al. (2024) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 29

Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity

Christensen, B. J., Iepsen, E. W., Lundgren, J., Holm, L., Madsbad, S., Holst, J. J., & Torekov, S. S. (2017) · Obesity Facts

Eating Disorders and BehaviorsNutrition, Health and Food Behavior

Cited by 28

Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

Anholm, C., Kumarathurai, P., Samkani, A., Pedersen, L. R., Boston, R. C., Nielsen, O. W., Kristiansen, O. P., Fenger, M., Madsbad, S., Sajadieh, A., et al. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 22

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet

Jensen, S. B. K., Lundgren, J. R., Janus, C., Juhl, C. R., Olsen, L. M., Rosenkilde, M., Holst, J. J., Stallknecht, B. M., Madsbad, S., & Torekov, S. S. (2019) · BMJ Open

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 20

Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes

Wendt, S. L., Ranjan, A., Møller, J. K., Schmidt, S., Knudsen, C. B., Holst, J. J., Madsbad, S., Madsen, H., Nørgaard, K., & Jørgensen, J. B. (2017) · Journal of Diabetes Science and Technology

Diabetes Management and ResearchPancreatic function and diabetes

Cited by 20

Major rapid weight loss induces changes in cardiac repolarization

Vedel-Larsen, E., Iepsen, E. W., Lundgren, J., Graff, C., Struijk, J. J., Hansen, T., Holst, J. J., Madsbad, S., Torekov, S., & Kanters, J. K. (2016) · Journal of Electrocardiology

Cardiac electrophysiology and arrhythmiasCardiovascular Effects of Exercise

Cited by 17

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

Iepsen, E. W., Zhang, J., Hollensted, M., Madsbad, S., Hansen, T., Holst, J. J., Jørgensen, N. R., Holm, J.-C., & Torekov, S. S. (2020) · Journal of Bone and Mineral Metabolism

Bone health and osteoporosis researchBone Metabolism and Diseases

Cited by 15

Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids

Fiorenza, M., Checa, A., Sandsdal, R. M., Jensen, S. B. K., Juhl, C. R., Noer, M. H., Bogh, N. P., Lundgren, J. R., Janus, C., Stallknecht, B. M., et al. (2024) · Cell Reports Medicine

Adipokines, Inflammation, and Metabolic DiseasesFibroblast Growth Factor Research

Cited by 14

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake

Bojsen-Møller, K. N., Svane, M. S., Martinussen, C., Dirksen, C., Jørgensen, N. B., Jensen, J.-E. B., Jensen, C. Z., Torekov, S. S., Kristiansen, V. B., Rehfeld, J. F., et al. (2023) · International Journal of Obesity

Bariatric Surgery and OutcomesRegulation of Appetite and Obesity

Cited by 13

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

von Scholten, B. J., Davies, M. J., Persson, F., Hansen, T. W., Madsbad, S., Endahl, L., Jepsen, C. H., & Rossing, P. (2017) · Journal of Diabetes and its Complications

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 11

No differential effects of porcine and human insulin on muscle sympathetic nerve activity during euglycaemia or hypoglycaemia

Frandsen, H. A., Snitker, S., Christensen, N. J., & Madsbad, S. (1996) · Clinical Physiology

Diabetes Management and ResearchPancreatic function and diabetes

Cited by 7